# Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

> **NCT00058461** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 82 (estimated)

## Conditions studied

- B-cell Childhood Acute Lymphoblastic Leukemia
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- L3 Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma

## Interventions

- **DRUG:** ifosfamide
- **DRUG:** etoposide
- **BIOLOGICAL:** rituximab
- **DRUG:** carboplatin
- **BIOLOGICAL:** filgrastim
- **DRUG:** methotrexate
- **DRUG:** cytarabine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00058461
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058461, "Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00058461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*